Alpha Tau Medical Ltd(DRTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 14 at 5:48 PM ET (Korea 9/15 06:48)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.04 | Insider Own | 20.28% | Shs Outstand | 92.3M | Perf Week | -4.19% |
| Market Cap | 1.30B | Forward P/E | - | EPS next Y | 44.1% | Insider Trans | -0.72% | Shs Float | 72.0M | Perf Month | -0.69% |
| Enterprise Value | 1.21B | PEG | - | EPS next Q | -0.15 | Inst Own | 9.26% | Short Float | 4.3% | Perf Quarter | 46.19% |
| Income | -0.09B | P/S | - | EPS this Y | -80.57% | Inst Trans | 12.99% | Short Ratio | 4.56 | Perf Half Y | 100.84% |
| Sales | 0.00B | P/B | 30.18 | EPS next 5Y | 10.86% | ROA | -75.51% | Short Interest | 3.09M | Perf YTD | 190.91% |
| Book/sh | 0.48 | P/C | 12.41 | EPS past 3/5Y | 0.15% -19.21% | ROE | -141.68% | 52W High | -5.08% ($15.17) | Perf Year | 277.95% |
| Cash/sh | 1.16 | P/FCF | - | Sales past 3/5Y | - | ROIC | -159.91% | 52W Low | 319.83% ($3.43) | Perf 3Y | 335.05% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -115.15% | Gross Margin | - | Volatility(W/M) | 5% 4.38% | Perf 5Y | 46.79% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.7 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.09 | EPS Q/Q | -301.43% | Profit Margin | - | RSI (14) | 53.69 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.09 | Sales Q/Q | - | SMA20 | -0.83% ($14.52) | Beta | 1.23 | Target Price | $17.8 |
| Payout | - | Debt/Eq | 0.34 | Earnings | 2026/8/10 | SMA50 | 6.41% ($13.53) | Rel Volume | 0.57 | Prev Close | $14.43 |
| Employees | 112 | LT Debt/Eq | 0.31 | EPS/Sales Surpr. | -256.14% -98.27% | SMA200 | 59.05% ($9.05) | Avg Volume(3M) | 0.68M | Price | $14.4 |
| IPO | 2021/3/8 | Option/Short | Yes/Yes | Trades | 3569 | Volume | 386,061 | Change | -0.21% |
Company
DRTS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🔬 Alpha Tau Medical (DRTS) is a clinical-stage oncology company developing Diffusing Alpha-emitter Radiation Therapy (Alpha DaRT) technology for the treatment of solid tumors. Its approach involves radioactive sources implanted directly into the tumor that continuously release short-lived alpha-emitting atoms to destroy the tumor locally. The company is expanding its clinical trials to include a range of solid tumor indications, including skin cancer.
Over the past 1 year, on the higher side
5% below its 1-year high.
DRTS has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -80.6% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +335.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 9.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IZRL 0.02%
EHLS 0.01%It ranks #4 in the industry
Based on market cap of $1B.
DRTS $1B PER -
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is DRTS?
DRTS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DRTS?
The market cap of DRTS is approximately $1.3B, ranking 2,433 within its sector.
What is the 52-week high and low for DRTS?
DRTS has recorded a 52-week high of $15.17 and a low of $3.43.
